India's Cipla and Ranbaxy Laboratories (owned by Japan's Daiichi Sankyo) both announced novel combination therapies for on World Malaria Day — with eyes on markets in India, Africa, South America and Southeast Asia. The products — Ranbaxy’s Synriam and Cipla’s Meflian Plus — are combinations of existing molecules arterolane maleate...